Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Product update

Caution with concomitant Zelboraf and radiation treatment

The summary of product characteristics for Zelboraf (vemurafenib; Roche) now states that cases of radiation recall and radiation sensitisation have been reported in patients treated with radiation either prior, during, or subsequent to vemurafenib treatment. Therefore, vemurafenib should be used with caution when given concomitantly or sequentially with radiation treatment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200189

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.